Moreover, a significant 15.9% reduction in the serum levels of the prostate cancer recurrence marker PSA (Prostate-specific antigen) was observed in the oleocanthal-treated mice, as compared to the placebo control-treated group. This evidence concerns the gene KLK3 and prostate carcinoma.